Journey Medical Corporation (NASDAQ:DERM) Q2 2023 Earnings Conference Call August 8, 2023 4:00 PM ET
Company Participants
Matt Blazei - CoreIR
Claude Maraoui - Co-Founder, President and Chief Executive Officer
Joseph Benesch - Interim Chief Financial Officer
Srinivas Sidgiddi - Vice President of R&D
Neal Bhatia - Director of Clinical Dermatology at Therapeutics Clinical Research
Conference Call Participants
Scott Henry - Roth capital
Kalpit Patel - B. Riley Securities
Operator
Ladies and Gentleman, thank you for standing by. Good afternoon and welcome to Journey Medical Second Quarter 2023 Financial Results and Corporate Update conference call. At this time all participants are in listen-only mode. [Operator Instructions].
I would like now to turn the call over to Mr. Matt Blazei of CoreIR, the company's investor relations firm. Please go ahead, sir.
Matt Blazei
Good afternoon and thank you for participating in today's conference call. Joining me from Journey Medical Corporation's leadership team are Claude Maraoui, Co-Founder, President & Chief Executive Officer; Joe Benesch, Interim Chief Financial Officer; Dr. Srini Sidgiddi, Vice President of Research and Development; and joining us to the Q&A session will be Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research .
During this call, management will be making forward-looking statements including statements that address among other things, Journey Medical's expectations for future performance, operational results, financial condition and receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q, the Form 8-K filed with the SEC today, and the company's press release that accompanies this call, particularly the cautionary statements in it.
Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP. For a reconciliation of this non-GAAP financial measure to net loss, it's most directly comparable GAAP financial measure, please to the reconciliation table located in the company's earnings press release.
The content of this call contains time-sensitive information that is accurate only as of today, August 8, 2023. Except as required by law, Journey Medical disclaims, any obligations to publicly update or revise any information to reflect events or circumstances that occur after this call.